Cargando…
IGF-1R down regulates the sensitivity of hepatocellular carcinoma to sorafenib through the PI3K / akt and RAS / raf / ERK signaling pathways
BACKGROUND: Insulin-like growth factor-1 receptor (IGF-1R) promotes cell proliferation and migration and inhibitsapoptosis, all of which can contribute to the development of cancers. METHOD: This study investigated the effect and mechanism of IGF-1R in mediating the desensitization of hepatocellular...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875405/ https://www.ncbi.nlm.nih.gov/pubmed/36698167 http://dx.doi.org/10.1186/s12885-023-10561-7 |
_version_ | 1784877953509752832 |
---|---|
author | Cai, Wenpeng Ma, Yongfang Song, Li Cao, Niandie Gao, Jiafeng Zhou, Shuping Tang, Xiaolong |
author_facet | Cai, Wenpeng Ma, Yongfang Song, Li Cao, Niandie Gao, Jiafeng Zhou, Shuping Tang, Xiaolong |
author_sort | Cai, Wenpeng |
collection | PubMed |
description | BACKGROUND: Insulin-like growth factor-1 receptor (IGF-1R) promotes cell proliferation and migration and inhibitsapoptosis, all of which can contribute to the development of cancers. METHOD: This study investigated the effect and mechanism of IGF-1R in mediating the desensitization of hepatocellular carcinoma (HCC) to sorafenib. RESULTS: IGF-1R, highly expressed in the HCC cell lines SK-Hep1 and HepG2, promotes cell proliferation, migration, and anti-apoptosis through PI3K / Akt and RAS / Raf / ERK signaling pathways, resulting in HCC resistance to sorafenib. Knockdown of IGF-1R by RNA interference decreased proliferation and cell migration and upregulation of sorafenib-induced apoptosis of HCC cells. In vivo studies demonstrated that IGF-1R knockdown inhibited the growth of SK-Hep1 xenografts. CONCLUSION: These data are evidence that IGF-1R participates in regulating the survival and cell growth of HCC through the PI3K / Akt and RAS / Raf / ERK signaling pathways. Intervention in the expression of IGF-1R may increase the inhibitory effect of sorafenib on HCC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-023-10561-7. |
format | Online Article Text |
id | pubmed-9875405 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-98754052023-01-26 IGF-1R down regulates the sensitivity of hepatocellular carcinoma to sorafenib through the PI3K / akt and RAS / raf / ERK signaling pathways Cai, Wenpeng Ma, Yongfang Song, Li Cao, Niandie Gao, Jiafeng Zhou, Shuping Tang, Xiaolong BMC Cancer Research BACKGROUND: Insulin-like growth factor-1 receptor (IGF-1R) promotes cell proliferation and migration and inhibitsapoptosis, all of which can contribute to the development of cancers. METHOD: This study investigated the effect and mechanism of IGF-1R in mediating the desensitization of hepatocellular carcinoma (HCC) to sorafenib. RESULTS: IGF-1R, highly expressed in the HCC cell lines SK-Hep1 and HepG2, promotes cell proliferation, migration, and anti-apoptosis through PI3K / Akt and RAS / Raf / ERK signaling pathways, resulting in HCC resistance to sorafenib. Knockdown of IGF-1R by RNA interference decreased proliferation and cell migration and upregulation of sorafenib-induced apoptosis of HCC cells. In vivo studies demonstrated that IGF-1R knockdown inhibited the growth of SK-Hep1 xenografts. CONCLUSION: These data are evidence that IGF-1R participates in regulating the survival and cell growth of HCC through the PI3K / Akt and RAS / Raf / ERK signaling pathways. Intervention in the expression of IGF-1R may increase the inhibitory effect of sorafenib on HCC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-023-10561-7. BioMed Central 2023-01-25 /pmc/articles/PMC9875405/ /pubmed/36698167 http://dx.doi.org/10.1186/s12885-023-10561-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Cai, Wenpeng Ma, Yongfang Song, Li Cao, Niandie Gao, Jiafeng Zhou, Shuping Tang, Xiaolong IGF-1R down regulates the sensitivity of hepatocellular carcinoma to sorafenib through the PI3K / akt and RAS / raf / ERK signaling pathways |
title | IGF-1R down regulates the sensitivity of hepatocellular carcinoma to sorafenib through the PI3K / akt and RAS / raf / ERK signaling pathways |
title_full | IGF-1R down regulates the sensitivity of hepatocellular carcinoma to sorafenib through the PI3K / akt and RAS / raf / ERK signaling pathways |
title_fullStr | IGF-1R down regulates the sensitivity of hepatocellular carcinoma to sorafenib through the PI3K / akt and RAS / raf / ERK signaling pathways |
title_full_unstemmed | IGF-1R down regulates the sensitivity of hepatocellular carcinoma to sorafenib through the PI3K / akt and RAS / raf / ERK signaling pathways |
title_short | IGF-1R down regulates the sensitivity of hepatocellular carcinoma to sorafenib through the PI3K / akt and RAS / raf / ERK signaling pathways |
title_sort | igf-1r down regulates the sensitivity of hepatocellular carcinoma to sorafenib through the pi3k / akt and ras / raf / erk signaling pathways |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875405/ https://www.ncbi.nlm.nih.gov/pubmed/36698167 http://dx.doi.org/10.1186/s12885-023-10561-7 |
work_keys_str_mv | AT caiwenpeng igf1rdownregulatesthesensitivityofhepatocellularcarcinomatosorafenibthroughthepi3kaktandrasraferksignalingpathways AT mayongfang igf1rdownregulatesthesensitivityofhepatocellularcarcinomatosorafenibthroughthepi3kaktandrasraferksignalingpathways AT songli igf1rdownregulatesthesensitivityofhepatocellularcarcinomatosorafenibthroughthepi3kaktandrasraferksignalingpathways AT caoniandie igf1rdownregulatesthesensitivityofhepatocellularcarcinomatosorafenibthroughthepi3kaktandrasraferksignalingpathways AT gaojiafeng igf1rdownregulatesthesensitivityofhepatocellularcarcinomatosorafenibthroughthepi3kaktandrasraferksignalingpathways AT zhoushuping igf1rdownregulatesthesensitivityofhepatocellularcarcinomatosorafenibthroughthepi3kaktandrasraferksignalingpathways AT tangxiaolong igf1rdownregulatesthesensitivityofhepatocellularcarcinomatosorafenibthroughthepi3kaktandrasraferksignalingpathways |